Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zimmer Biomet HoldingsXSWX:ZBH 77 Intrinsic Value: Projected FCF is CHF110.17 as of Sep. 12, 2026. GuruFocus rates XSWX:ZBH with a GF Score™ of 77/100 and a GF Value™ of CHF102.05 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 414 Medical Devices & Instruments companies, Zimmer Biomet Holdings ranks better than 82.61% on this metric.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
The historical rank and industry rank for Zimmer Biomet Holdings's Intrinsic Value: Projected FCF or its related term are showing as below:
XSWX:ZBH'
s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 0.64 Med: 1.13 Max: 1.51
Current: 0.69
During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Zimmer Biomet Holdings was 1.51. The lowest was 0.64. And the median was 1.13.
XSWX:ZBH's Price-to-Projected-FCF is ranked better than 82.61% of 414
companies
in the Medical Devices & Instruments industry
Industry Median: 1.45
vs XSWX:ZBH: 0.69
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
Zimmer Biomet Holdings's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF
=
Share Price
/
Intrinsic Value: Projected FCF
=
75.50
/
104.47365947689
=
0.72
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zimmer Biomet Holdings Intrinsic Value: Projected FCF Related Terms
Zimmer Biomet Holdings Intrinsic Value: Projected FCF Historical Data
* Premium members only.
The historical data trend for Zimmer Biomet Holdings's Intrinsic Value: Projected FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:ZBH vs STE, PEN, GMED: Intrinsic Value: Projected FCF Comparison
For the Medical Devices subindustry, Zimmer Biomet Holdings's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zimmer Biomet Holdings Price-to-Projected-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Zimmer Biomet Holdings's Price-to-Projected-FCF distribution charts can be found below:
* The bar in red indicates where Zimmer Biomet Holdings's Price-to-Projected-FCF falls into.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Intrinsic Value: Projected FCF of CHF110.17 mean?
Zimmer Biomet Holdings (XSWX:ZBH) has a Intrinsic Value: Projected FCF of CHF110.17 as of Sep. 12, 2026. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Zimmer Biomet Holdings and its competitors. According to the industry distribution chart, Zimmer Biomet Holdings ranks #72 out of 414 companies in the Medical Devices & Instruments industry, placing it in the top 17.4%.
Is Zimmer Biomet Holdings' Intrinsic Value: Projected FCF too high?
Zimmer Biomet Holdings' current Intrinsic Value: Projected FCF is CHF110.17. Based on the distribution chart, Zimmer Biomet Holdings ranks #72 out of 414 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Zimmer Biomet Holdings has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zimmer Biomet Holdings' Intrinsic Value: Projected FCF compare to STE and PEN?
According to the Medical Devices & Instruments industry distribution chart, Zimmer Biomet Holdings ranks #72 out of 414 companies for Intrinsic Value: Projected FCF. This places Zimmer Biomet Holdings in the top 17% of its industry — outperforming the majority of peers. The industry median Intrinsic Value: Projected FCF is 1.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intrinsic Value: Projected FCF for a Medical Devices & Instruments company?
The median Intrinsic Value: Projected FCF among Medical Devices & Instruments companies is 1.45, based on 414 companies in the industry. Companies in the top quartile (top 25%) have a Intrinsic Value: Projected FCF significantly above this median, while those in the bottom quartile fall well below. However, Intrinsic Value: Projected FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intrinsic Value: Projected FCF mean?
A high Intrinsic Value: Projected FCF can signal that a stock is expensive relative to its fundamentals. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Zimmer Biomet Holdings and its competitors. For the Medical Devices & Instruments industry, the median Intrinsic Value: Projected FCF is 1.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zimmer Biomet Holdings's current Intrinsic Value: Projected FCF is CHF110.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zimmer Biomet Holdings stock overvalued right now?
Based on GuruFocus' analysis, Zimmer Biomet Holdings (XSWX:ZBH) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF102.05, compared to a current price of CHF75.50 — trading 26% below its estimated fair value. The current Intrinsic Value: Projected FCF is CHF110.17. Zimmer Biomet Holdings' overall GF Score™ is 77/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intrinsic Value: Projected FCF calculated?
Intrinsic Value: Projected FCF is calculated from a company's financial statements. For Zimmer Biomet Holdings (XSWX:ZBH), the current Intrinsic Value: Projected FCF is CHF110.17 as of Sep. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zimmer Biomet Holdings (XSWX:ZBH) Overvalued in 2026?
Based on GuruFocus' analysis, Zimmer Biomet Holdings stock appears to be undervalued.
The current stock price of CHF75.50 is trading 26% below its estimated GF Value™ of CHF102.05.
GuruFocus considers Zimmer Biomet Holdings to be Modestly Undervalued.
Key valuation signals for XSWX:ZBH:
Intrinsic Value: Projected FCF: CHF110.17
GF Value™: CHF102.05 vs. price of CHF75.50 (26% below fair value)
No single metric tells the full story. See the XSWX:ZBH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
77GF Score
Get the complete analysis for XSWX:ZBH
Intrinsic Value: Projected FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:ZBH has been successfully added to your 
